BARRY D KAHAN, M.D.
Radiology in Houston, TX

6355639, Mar 12, 2002

Feb 16, 2000

09/463537

Ting-Chao Chou - Paramus NJ
Joseph R. Bertino - Branford CT
Samuel J. Danishefsky - Englewood NJ
Barry D. Kahan - Houston TX

Sloan-Kettering Institute for Cancer Research - New York NY

A61K 31495

514250

The present invention provides a method for treating a subject in need of immunosuppression, comprising administering to the subject an effective amount of a compound having structure (I) wherein R , R and R are independently hydrogen, OH, NH , SH, halogen, C -C linear or branched chain alkyl, alkylmercapto, alkylamino, etc. ; wherein R and R are independently hydrogen, OH, C -C linear or branched chain alkyl, —CR R —CH(O)CH , —CR R —CH CHR , etc. ; wherein R and R are independently hydrogen halogen C -C linear or branched chain alkyl, etc. ; wherein R is hydrogen, C -C linear or branched chain alkyl, phenyl, alkylphenyl, dialkylphenyl, alkylmercapto, etc. ; and wherein R is hydrogen, C -C linear or branched chain acyl, benzoyl, alkylbenzoyl, etc. Also provided are methods of treating autoimmune disease and preventing organ graft rejection using N-acetylardeemin and related compounds.

6051232, Apr 18, 2000

Apr 15, 1997

8/842656

Rafik R. Ghobrial - Pearland TX
Stanislaw M. Stepkowski - Houston TX
Barry D. Kahan - Houston TX

Board of Regents, University of Texas System - Austin TX

A61K 39385, C07K 14705, C07K 14745

4241921

Chimeric MHC Class I molecules having a recipient-type N-terminus, a donor-type alpha-1 helical region, and a recipient-type alpha-2 domain induce tolerance to donor grafts when administered to the recipient at time of transplantation.

4228236, Oct 14, 1980

May 15, 1978

5/906036

Milda M. Jakstys - Chicago IL
Baldwin H. Tom - Houston TX
Barry D. Kahan - Houston TX

Northwestern University - Evanston IL

C12K 900

435 1

Carcinoembryonic antigen (CEA) is produced in vitro from the cell lines LS-180 (ATCC No. CL-187), LS-174T (ATCC No. CL-188), and cells derived therefrom. The CEA thus produced can be used as a standard source for radioimmunoassay procedures to determine CEA plasma levels.

7928062, Apr 19, 2011

Nov 5, 2007

11/935147

Robert A. Kirken - El Paso TX, US
Barry D. Kahan - Houston TX, US
Stanislaw M. Stepkowski - Pearland TX, US
Waldemar Priebe - Houston TX, US
Izabela Fokt - Spring TX, US
Szymon Kosinski - Menomonee Falls WI, US

Board of Regents of the University of Texas System - Austin TX

A61K 38/00, A61K 31/12, A61K 31/13, A01N 35/00

514 11, 514690, 514659

Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e. g. , T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.

7365096, Apr 29, 2008

Dec 9, 2003

10/731769

Robert A. Kirken - Conroe TX, US
Barry D. Kahan - Houston TX, US
Stanislaw M. Stepkowski - Pearland TX, US
Waldemar Priebe - Houston TX, US
Izabela Fokt - Spring TX, US
Szymon Kosinski - Menomonee Falls WI, US

Board of Regents, The University of Texas System - Austin TX

A61K 31/21, A61K 31/13, A61K 31/12, A61K 8/73

514513, 514 80, 514690, 514659, 424 49

Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e. g. , T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.